Patients with rheumatoid arthritis who switched biologics incurred higher costs than patients who persisted on biologics. Etanercept appeared to be associated with the lowest costs.
Alex Mutebi, PhD
Advertisement
Articles by Alex Mutebi, PhD
This review assesses the current molecular testing landscape for non–small-cell lung cancer in the United States.
Advertisement
Latest Updated Articles
- eAppendix
February 17th 2018
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Extension Studies in TPIP Show Promise in PAH, PH-ILD
3
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5